HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Statin Drug Makes SPORT Of Supplements In Pharma-Funded, 28-Day Trial On Lowering LDL

Executive Summary

Primary and secondary endpoint results in “Supplements, Placebo, or Rosuvastatin” study conducted by Cleveland Clinic include no difference, after four weeks, in total cholesterol and blood triglyceride measures between subjects receiving placebo and those using fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice.

You may also be interested in...

QHC For Vitamin D, Omega-3 Helping Prevent Autoimmune Conditions Has VITAL Data Support

Trial for 5.3 years with more than 25,000 consumers 50 and older pointing to a link between vitamin D and imegta-3s and reducing autoimmune disease isn’t the first with results from VITAL. “It's a big one that we've been watching for a number of years. And it's exciting, some exciting outcomes,” says CRN scientific and regulatory affairs exec Andrea Wong.

AZ Sells EU Rights To Former Jewel In The Crown, Crestor

The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.

With Added Indication, Amarin Says Vascepa No ‘Fish Oil’ Like Omega-3s

In Amarin’s “education process” about indication as an add-on to statin therapy to help cut CV risk in high-risk patients, it “will also be emphasizing how Vascepa is different from” Rx drugs fenofibrate and niacin “and omega-3 mixtures,” says CEO John Thero.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts